Notice of General Meeting/Proxy Form
Released
Released
Announcement PDF
Page 1
RENERVE LIMITED
ACN 614 848 216
Notice of General Meeting
Explanatory Memorandum & Proxy Form
Notice is given that the Meeting will be held at:
DATE: Monday 5 January 2026
TIME: 10.00AM (AEDT)
VENUE: Held as a Virtual Meeting
The business of Meeting affects your shareholding and your vote is important.
This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should
vote, they should seek advice from their professional advisers prior to voting.
Page 2
RENERVE LIMITED
Notice of General Meeting
Notice is given that the 2026 General Meeting of the Shareholders of ReNerve Limited (ACN 614 848 216)
(ReNerve or the Company) will be Monday 5 January at 10.00am (AEDT) virtually.
Shareholders are strongly encouraged to submit their proxies as early as possible and in any event prior to the cut-
off for proxy voting as set out in the Notice. To lodge your proxy, please follow the directions on your personalised
proxy form which will be enclosed with a copy of the Notice, delivered to you by email or post (depending on your
communication preferences). If a Shareholder has nominated for electronic communications, they will receive the
Notice by email. Other Shareholders will receive a postcard with a URL link to the Notice and Proxy Form.
MEETING ATTENDANCE
Shareholders who wish to attend the meeting in person are requested to notify and register their attendance with
the Company at info@renerve.com.au.
Shareholders do not need to attend the Meeting to cast their vote/s and are encouraged to submit their votes and
appoint the Chairperson as their proxy. Detailed instructions for lodging votes and appointment of a proxy are
included in the accompanying Notice of Meeting and Proxy Form.
VOTING ELIGIBILITY
The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Act 2001 (Cth) that the persons
eligible to vote at the Meeting are those who are registered Shareholders at 10.00am AEDT on 1 January 2026.
If you have any queries on how to cast your votes, please email Automic at: meetings@automicgroup.com.au.
VOTING BY ATTORNEY
Shareholders intending to attend the Meeting by attorney must ensure that they have provided the original or a
certified copy of the power of attorney to the Company, in the same manner prescribed below for the giving of proxy
forms to the Company.
VOTING BY PROXY
To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance
with the instructions set out on the Proxy Form.
In accordance with section 249L of the Corporations Act, Shareholders are advised that:
• each Shareholder has a right to appoint a proxy;
• the proxy need not be a Shareholder; and
• a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the
proportion or number of votes each proxy is appointed to exercise. If the member appoints two proxies
and the appointment does not specify the proportion or number of the member’s votes, then in accordance
with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.
Proxy vote if appointment specifies way to vote
Section 250BB(1) of the Corporations Act provides that an appointment of a proxy may specify the way the proxy
is to vote on a particular Resolution. If an appointment of a proxy specifies the way the proxy is to vote on a
particular Resolution:
• The proxy need not vote on a show of hands, but if the proxy does so, the proxy must vote that way (i.e.
as directed); and
• If the proxy has two or more appointments that specify different ways to vote on the Resolution, the proxy
must not vote on a show of hands; and
• If the proxy is the Chair at which the Resolution is voted on, the proxy must vote on a poll, and must vote
that way (i.e. as directed); and
Page 3
• If the proxy is not the Chair, the proxy need not vote on the poll, but if the proxy does so, the proxy must
vote that way (i.e. as directed); and
If the proxy is not the Chair and at the Meeting, a poll is duly demanded on the Resolution and either of the following
applies:
• the proxy is not recorded as attending the Meeting; or
• the proxy does not vote on the Resolution,
the Chair is taken, before voting on the Resolution closes, to have been appointed as the proxy for the purposes of
voting on the Resolution of the Meeting.
If you appoint the Chair of the Meeting as your proxy, you can direct the Chair to vote for or against or abstain from
voting on the Resolutions.
The Chair intends to vote undirected proxies in favour of Resolutions 2 – 12.
CORPORATE REPRESENTATIVES
A Shareholder that is a body corporate may appoint an individual to act as its representative at the Meeting by
providing a duly executed Certificate of Appointment of Corporate Representative (Certificate). Unless otherwise
specified in the Certificate, the representative may exercise all or any of the powers that the body corporate may
exercise at the Meeting or in voting on a Resolution. A Certificate is available upon request from Automic.
Certificates must be lodged in advance of the Meeting with Automic no less than 24 hours prior to the Meeting.
QUESTIONS AND COMMENTS BY SHAREHOLDERS AT THE GENERAL MEETING
In accordance with the Corporations Act, a reasonable opportunity will be given to Shareholders to ask questions
about or make comments on the management of the Company at the Meeting.
Shareholders may submit any written questions addressed to the Company via the address on the proxy form or to
ReNerve Limited via email at info@renerve.com.au no later than 48 hours prior to the Meeting.
The Company will either answer the questions at the Meeting or table written answers to them at the Meeting. If
written answers are tabled at the Meeting, they will be made available to Shareholders as soon as practicable after
the Meeting.
Shareholders may also submit questions to the Board related to any of the resolutions to be considered. These
questions will be responded to by the Board during the Meeting. As above, questions should be submitted to
info@renerve.com.au no later than 48 hours prior to the Meeting.
ENQUIRIES
Shareholders are asked to contact the Company at info@renerve.com.au or the Company Secretary at
david.lilja@dlkadvisory.com.au or on +61 3 9923 1222 if they have any queries in respect of the matters set out in
these documents.
Page 4
RENERVE LIMITED
Notice of General Meeting
Notice is given that the 2026 General Meeting of the Shareholders of ReNerve Limited (ACN 614 848 216)
(ReNerve or the Company) will be held on Monday 5 January 2026 at 10.00am (AEDT) virtually.
The Explanatory Memorandum to this Notice of Meeting (Notice) provides additional information on matters to be
considered at the General Meeting. The Explanatory Memorandum and the Proxy Form are part of this Notice.
ORDINARY BUSINESS
RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF 21,581,587 TRANCHE 1 PLACEMENT SHARES
To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary
resolution:
“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of
21,581,587 Tranche 1 Placement Shares, on the terms and conditions specified in the Explanatory Memorandum
which accompanies and forms part of this Notice.”
A voting exclusion statement applies to this Resolution.
RESOLUTION 2 – APPROVAL TO ISSUE 5,085,080 TRANCHE 2 PLACEMENT SHARES
To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary
resolution:
“That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of
5,085,080 Tranche 2 Placement Shares, on the terms and conditions specified in the Explanatory Memorandum
which accompanies and forms part of this Notice.”
A voting exclusion statement applies to this Resolution.
RESOLUTION 3 – APPROVAL TO ISSUE 26,666,667 ONE FOR ONE FREE ATTACHING OPTIONS
To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary
resolution:
“That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of
26,666,667 Attaching Options, on the terms and conditions specified in the Explanatory Memorandum which
accompanies and forms part of this Notice.”
A voting exclusion statement applies to this Resolution.
RESOLUTION 4 – APPROVAL TO ISSUE 4,000,000 LEAD MANAGER OPTIONS
To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary
resolution:
“That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of
4,000,000 Joint Lead Manager Options, on the terms and conditions specified in the Explanatory Memorandum
which accompanies and forms part of this Notice.”
A voting exclusion statement applies to this Resolution.
Page 5
VOTING EXCLUSIONS
1. Under the Corporations Act and ASX Listing Rule 14.11, the Company will disregard any votes cast in favour
of the resolutions by or on behalf of:
• the names person or class of persons excluded from voting as set out in the Explanatory Statement; or
• an associate of that person or those persons.
However, this does not apply to a vote cast in favour of a resolution by:
• a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with
directions given to the proxy or attorney to vote on the resolution in that way; or
• the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in
accordance with a direction given to the chair to vote on the resolution as the chair decides; or
• a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary
provided the following conditions are met.
o the beneficiary provides written confirmation to the holder that the beneficiary is not excluded
from voting, and is not an associate of the person excluded from voting, on the resolution; and
o the holder votes on the resolution in accordance with directions given by the beneficiary to the
holder to vote in that way.
2. KMP that may have a vested interest in the outcome of a Resolution have restrictions on voting on those
Resolutions. KMP include members of the Board and certain senior executives, as set out in the RNV Annual
Report. The Corporations Act restricts KMP and their Closely Related Parties from voting in certain
circumstances.
3. Under the Corporations and ASX Listing Rules, voting exclusions apply to the following Resolutions and further
detail is provided in the Explanatory Statement:
• Resolution 1 – Ratification of Prior Issue of 21,581,587 Tranche 1 Placement Shares;
• Resolution 2 – Approval to Issue 5,085,080 Tranche 2 Placement Shares;
• Resolution 3 – Approval to Issue 26,666,667 one for one free Attaching Options; and
• Resolution 4 – Approval to Issue 4,000,000 Lead Manager Options.
DATE: 2 December 2025
BY ORDER OF THE BOARD
DAVID LILJA
COMPANY SECRETARY
Page 6
EXPLANATORY MEMORANDUM
This Explanatory Memorandum has been prepared to provide information which the Directors believe to be material
to Shareholders in deciding whether or not to pass the Resolutions.
RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF 21,581,587 TRANCHE 1 PLACEMENT SHARES
1.1 General
As announced to the ASX on 20 November 2025 the Company completed a capital raising to new and existing
professional and sophisticated investors, to raise approximately $3,200,000 (before costs) (Placement) by the
issuance of 26,666,667 new shares (Placement Shares) via two tranches.
The Placement comprises two tranches:
• Tranche one raised $2,589,790 (before costs) and was made within the Company’s capacity under ASX
Listing Rule 7.1 (21,581,587 Shares) (“Tranche 1 Placement Shares”) (“Tranche 1 Placement”).
• Tranche two raised $610,209 (before costs) and is subject to shareholder approval per Resolution 2
below (5,085,080 Shares) (“Tranche 2 Placement Shares”) (“Tranche 2 Placement”).
• The 26,666,667 Placement Shares were issued (in respect of the Tranche 1 Placement Shares) and are
to be issued (in respect of the Tranche 2 Placement Shares) with a one for one free attaching option
(“Attaching Options”) with an exercise price of $0.18 and a maturity date of two years from the date of
issue, subject to shareholder approval per Resolution 3 below (“Attaching Options”).
The Placement represented a 22.6% discount to the last closing price of the Company’s shares on 17 November
2025 and a 28.2% discount to the 15-day VWAP.
ASX Listing Rule 7.1 limits the number of equity securities that a company may issue without member approval to
15% of the issued capital of the Company in any 12-month period (subject to certain exceptions).
ASX Listing Rule 7.4 allows an issue of securities to be subsequently approved by shareholders and treated as
having been made with approval of shareholders for the purpose of ASX Listing Rule 7.1. The Company is seeking
subsequent shareholder approval of the issue of the Tranche 1 Placement Shares pursuant to ASX Listing Rule
7.4.
All of the Tranche 1 Placement Shares being the subject of this resolution are ordinary fully paid shares which rank
equally with all of the Company’s existing ordinary fully paid shares and are quoted on the ASX. The Tranche 1
Placement Shares were issued at A$0.12 per share.
1.2 Technical Information required by Listing Rule 14.1A
If Resolution 1 is passed, the Tranche 1 Placement Shares will be excluded in calculating the Company’s 15% limit
in ASX Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without
Shareholder approval over the 12-month period following the date of issue of the Tranche 1 Placement Shares.
If Resolution 1 is not passed, the Tranche 1 Placement Shares will be included in calculating the Company’s 15%
limit in ASX Listing Rule 7.1, effectively decreasing the number of equity securities that the Company can issue
without shareholder approval over the 12-month period following the date of issue of the Tranche 1 Placement
Shares.
Page 7
Information required by Listing Rule 7.5
Pursuant to and in accordance with ASX Listing Rule 7.5, the following information is provided in relation to
Resolution 1:
• the Tranche 1 Placement Shares were issued to professional and sophisticated investors. The recipients
were identified through a bookbuild process, which involved Alpine Capital Pty Ltd (Alpine) and SP
Corporate Advisory Pty Ltd (Spark Plus) seeking expressions of interest to participate in the capital raising
from non-related parties of the Company;
• 21,581,587 Tranche 1 Placement Shares were issued and the Tranche 1 Placement Shares issued were
all fully paid ordinary shares in the capital of the Company issued under the same terms and conditions
as the Company’s existing Shares;
• the Tranche 1 Placement Shares were issued 1 December 2025;
• the issue price was $0.12 per share. The Company has not and will not receive any other consideration
for the issue of the Tranche 1 Placement Shares;
• the purpose of the issue was to raise capital to fund:
- acceleration of the sales and marketing programmes for the Company's product lines
already on market, the NervAlign® Nerve Cuff and EmpliQ ranges;
- ongoing development of new products that the Company is planning to bring to market,
including its range of nerve conduit products and its nerve guide matrix product;
- strengthening of the Company’s sales team; and
- working capital.
• the Tranche 1 Placement Shares were not issued under an agreement.
Voting Exclusion Statement
In accordance with the Listing Rules, the Company will disregard any votes cast in favour of the Resolution 1 by or
on behalf of a person or persons who participated in the Placement or is counterparty to the agreement being
approved (namely those who participated in the Placement) or an associate if that person or those persons.
However, this does not apply to a vote cast in favour of a resolution by:
• a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with
directions given to the proxy or attorney to vote on the resolution in that way; or
• the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in
accordance with a direction given to the chair to vote on the resolution as the chair decides; or
• a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary
provided the following conditions are met.
- the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from
voting, and is not an associate of the person excluded from voting, on the resolution; and
- the holder votes on the resolution in accordance with directions given by the beneficiary to the holder
to vote in that way.
RESOLUTION 2 – APPROVAL TO ISSUE 5,085,080 TRANCHE 2 PLACEMENT SHARES
2.1 General
As noted at Resolution 1, the Company announced the Placement to the ASX on 20 November 2025, and this
resolution seeks the approval to the issue of 5,085,080 new fully paid ordinary shares in relation to the Tranche 2
Placement that raised $610,209 before costs (the “Tranche 2 Placement”).
The Placement represented a 22.6% discount to the last closing price of the Company’s shares on 17 November
2025 and a 28.2% discount to the 15-day VWAP.
ASX Listing Rule 7.1 limits the number of equity securities that a company may issue without member approval to
15% of the issued capital of the Company in any 12-month period (subject to certain exceptions).
Page 8
All of the Tranche 2Placement Shares being the subject of this resolution are ordinary fully paid shares which rank
equally with all of the Company’s existing ordinary fully paid shares and are quoted on the ASX. The Placement
Shares will be issued at A$0.12 per share.
2.2 Technical information required by Listing Rule 14.1A
If Resolution 2 is passed, the Tranche 2 Placement Shares will be excluded in calculating the Company’s 15% limit
in ASX Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without
Shareholder approval over the 12-month period following the date of issue of the Tranche 2Placement Shares.
If Resolution 2 is not passed, the Tranche 2 Placement Shares will be included in calculating the Company’s 15%
limit in ASX Listing Rule 7.1, effectively decreasing the number of equity securities that the Company can issue
without shareholder approval over the 12-month period following the date of issue of the Tranche 2 Placement
Shares.
2.3 Information required by Listing Rule 7.3
Pursuant to and in accordance with ASX Listing Rule 7.3, the following information is provided in relation to
Resolution 2:
• the Tranche 2 Placement Shares will be issued to professional and sophisticated investors. The recipients
were identified through a bookbuild process, which involved Alpine and Spark Plus seeking expressions
of interest to participate in the capital raising from non-related parties of the Company;
• 5,085,080 Tranche 2 Placement Shares are all fully paid ordinary shares in the capital of the Company
issued under the same terms and conditions as the Company’s existing Shares;
• the Tranche 2 Placement Shares will be issued on 7 January 2026;
• the issue price was $0.12 per Placement Share. The Company has not and will not receive any other
consideration for the issue of the Placement Shares;
• the purpose of the issue was to raise capital to fund:
- acceleration of the sales and marketing programmes for the Company's product lines
already on market, the NervAlign® Nerve Cuff and EmpliQ ranges;
- ongoing development of new products that the Company is planning to bring to market,
including its range of nerve conduit products and its nerve guide matrix product;
- strengthening of the Company’s sales team; and
- working capital.
• the Tranche 2 Placement Shares will be not issued under an agreement.
2.4 Voting Exclusion Statement
In accordance with the Listing Rules, the Company will disregard any votes cast in favour of the Resolution 2 by or
on behalf of a person or persons who participated in the Placement or is counterparty to the agreement being
approved (namely those who participated in the Placement) or an associate if that person or those persons.
However, this does not apply to a vote cast in favour of a resolution by:
• a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with
directions given to the proxy or attorney to vote on the resolution in that way; or
• the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in
accordance with a direction given to the chair to vote on the resolution as the chair decides; or
• a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary
provided the following conditions are met.
- the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from
voting, and is not an associate of the person excluded from voting, on the resolution; and
- the holder votes on the resolution in accordance with directions given by the beneficiary to the holder
to vote in that way.
Page 9
RESOLUTION 3 – APPROVAL TO ISSUE 26,666,667 ONE FOR ONE FREE ATTACHING OPTIONS
3.1 General
As announced to the ASX on 20 November 2025 and summarised in Resolutions 1 and 2 above, subject to
Shareholder approval for the purposes of ASX Listing Rule 7.1, this resolution seeks the approval to the issue of
26,666,667 options, with an exercise price of $0.18 and a maturity date of two years from the date of issue to all
participants in the Placement on a one for one basis for all Placement Shares issued (“Attaching Options”).
ASX Listing Rule 7.1 limits the number of equity securities that a company may issue without member approval to
15% of the issued capital of the Company in any 12-month period (subject to certain exceptions). The Company is
seeking shareholder approval to issue the 26,666,667 Attaching Options pursuant to ASX Listing Rule 7.1.
3.2 Technical information required by ASX Listing Rule 14.1A
If Resolution 3 is passed, the Company will be able to proceed with the issue of the Attaching Options. In addition,
the issue of the Attaching Options will be excluded from the calculation of the number of equity securities that the
Company can issue without Shareholder approval under ASX Listing Rule 7.1.
If Resolution 3 is not passed, the Company will not be able to proceed with the issue of the Attaching Options.
3.3 Technical information required by ASX Listing Rule 7.3
Pursuant to and in accordance with ASX Listing Rule 7.3, the following information is provided in relation to
Resolution 3:
• the Attaching Options will be issued to the sophisticated investors who participated in the Placement;
• The Attaching Options are unlisted options;
• 26,666,667 Attaching Options to be issued on the terms and conditions as set out in the “Terms and
Conditions” below;
• the Attaching Options will be issued at the earliest practicable opportunity following the date of the meeting
and in any event no later than 1 month after the date of the meeting;
• the Attaching Options will be issued at a Nil issue price;
• the purpose of the issue is satisfy the Company’s commitment to investors under the Placement.
• the Attaching Options are not being issued under, or to fund, a reverse takeover.
3.4 Terms and Conditions
The following is a summary of the key terms and conditions of the Attaching Options:
• Entitlement
Each Attaching Options entitles the holder to subscribe for one Share upon exercise of the Attaching
Option.
• Exercise Price
The amount payable upon exercise of each Attaching Option is $0.18.
• Vesting Date
The Attaching Options will vest immediately on the date of issue.
• Expiry Date
Each Attaching Option will expire at two years from the date of issue. An Attaching Option not exercised
before the Expiry Date will automatically lapse on Expiry Date.
• Exercise Period
The Options are exercisable at any time and will expire on the Expiry Date.
Page 10
• Notice of Exercise
The Attaching Options may be exercised during the Exercise Period by notice in writing to the Company
and payment of the Exercise Price for each Attaching Option being exercised in Australian Currency by
means of payment acceptable to the Company.
• Exercise Date
A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise
and the date of receipt of the payment of the Exercise Price for each Attaching Option being exercised in
cleared funds.
• Consideration
The Attaching Options will be issued for nil cash consideration.
• Timing of Issue of Shares on Exercise
Within 14 business days of the Exercise Date, the Company will:
- issue the number of Shares required under these terms and conditions in respect of the
number of Attaching Options specified in the Notice of Exercise and for which cleared funds
have been received by the Company;
- if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act,
or, if the Company is unable to issue such a notice, lodge with the ASX a prospectus prepared
in accordance with the Corporations Act and do all such things necessary to satisfy section
708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require
disclosure to investors; and
- admit the Shares to the official list of the ASX at the time and apply for quotation on ASX of
Shares issued pursuant to the exercise of the Attaching Options.
• Shares Issued on Exercise
Shares issued on exercise of the Attaching Options rank equally with the then issued shares of the
Company
• Reconstruction of Capital
If at any time the issued capital of the Company is reconstructed, all rights of an Optionholder are to be
changed in a manner consistent with the Corporations Act and the ASX Listing Riles at the time of
reconstruction.
• Participation in New Shares
There are no participation rights or entitlements inherent in the Attaching Options and holders will not be
entitled to participate in new shares of capital offered to Shareholders during the currency of the
Attaching Options without exercising the Attaching Options.
• Change in Exercise Price
An Attaching Options does not confer the right to a change in Exercise Price or a change in the number of
underlying securities over which the Attaching Option can be exercised.
• Transferability
The Attaching Options are transferable subject to any restriction or escrow arrangements imposed by the
ASX or under the applicable Australian securities laws.
3.5 Voting Exclusion Statement
In accordance with the Listing Rules, the Company will disregard any votes cast in favour of the Resolution 3 by or
on behalf of a person or persons who participated in the Placement or is counterparty to the agreement being
approved (namely those who participated in the Placement) or an associate if that person or those persons.
However, this does not apply to a vote cast in favour of a resolution by:
• a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with
directions given to the proxy or attorney to vote on the resolution in that way; or
• the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in
accordance with a direction given to the chair to vote on the resolution as the chair decides; or
• a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary
provided the following conditions are met.
Page 11
- the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from
voting, and is not an associate of the person excluded from voting, on the resolution; and
- the holder votes on the resolution in accordance with directions given by the beneficiary to the holder
to vote in that way.
RESOLUTION 4 – APPROVAL TO ISSUE 4,000,000 LEAD MANAGER OPTIONS
4.1 General
As announced to the ASX on 20 November 2025 the Company completed a capital raising to new and existing
professional and sophisticated investors via an Issue of Placement Shares, with Alpine Capital Pty Ltd (“Alpine)
and SP Corporate Advisory Pty Ltd (“Spark Plus”) or (“Joint Lead Managers”) acting as Joint Lead Managers to
the Placement.
In accordance with the mandate between the Company and the Joint Lead Managers, in addition to a cash
completion fee, the Joint Lead Managers are to receive 4,000,000 Options (“Lead Manager Options”), subject to
the Company’s capacity to issue new securities.
ASX Listing Rule 7.1 limits the number of equity securities that a company may issue without member approval to
15% of the issued capital of the Company in any 12-month period (subject to certain exceptions). The Company is
seeking subsequent shareholder approval of the issue of Lead Manager Options pursuant to ASX Listing Rule 7.1.
4.2 Technical information required by ASX Listing Rule 14.1A
If Resolution 4 is passed, the Lead Manager Options will be excluded in calculating the Company’s 15% limit in
ASX Listing Rules 7.1, effectively increasing the number of equity securities the Company can issue without
Shareholder approval over the 12-month period following the date of issue of the Lead Manager Options.
If Resolution 4 is not passed, the Lead Manager Options will be included in calculating the Company’s 15% limit in
ASX Listing Rules 7.1, effectively decreasing the number of equity securities that the Company can issue without
shareholder approval over the 12-month period following the date of issue of the Lead Manager Options.
4.3 Technical information required by ASX
Share your feedback
Discover